Publicaciones en las que colabora con FRANCISCO BOLAS FERNÁNDEZ (38)

2023

  1. Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 183, pp. 74-91

  2. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers

    International journal of pharmaceutics, Vol. 635, pp. 122788

2022

  1. Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers

    Journal of Controlled Release, Vol. 341, pp. 716-732

2020

  1. Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis

    Molecules, Vol. 25, Núm. 6

  2. Nucleotides and AHCC Enhance Th1 Responses in Vitro in Leishmania-Stimulated/Infected Murine Cells

    Molecules, Vol. 25, Núm. 17

  3. Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing

    Pharmaceutical Research, Vol. 37, Núm. 7

  4. Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis

    International Journal of Pharmaceutics, Vol. 588

  5. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale

    International Journal of Pharmaceutics, Vol. 573

  6. Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases

    ACS Infectious Diseases, Vol. 6, Núm. 10, pp. 2647-2660

2019

  1. Repurposing butenafine as an oral nanomedicine for visceral leishmaniasis

    Pharmaceutics, Vol. 11, Núm. 7

2018

  1. Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 124, pp. 13-27

  2. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis

    Molecular Pharmaceutics, Vol. 15, Núm. 7, pp. 2570-2583

2017

  1. Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections

    Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106

2015

  1. Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles

    Molecular Pharmaceutics, Vol. 12, Núm. 2, pp. 420-431

2014

  1. Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose

    Drug Design, Development and Therapy, Vol. 8, pp. 1467-1479

  2. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp

    International Journal of Pharmaceutics, Vol. 473, Núm. 1-2, pp. 148-157

2013

  1. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations

    International Journal of Pharmaceutics, Vol. 447, Núm. 1-2, pp. 38-46

2012

  1. Enantiomerical pharmacokinetic prevalence of (+) albendazole sulphoxide in Trichinella spiralis muscle larvae

    Parasitology Research, Vol. 110, Núm. 2, pp. 993-999

2011

  1. Changed crystallinity of mebendazole solid dispersion: Improved anthelmintic activity

    International Journal of Pharmaceutics, Vol. 403, Núm. 1-2, pp. 23-28

2008

  1. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 5, pp. 1125-1131